Imprimis Pharmaceuticals has filed a Form 8-K with the SEC to launch a subsidiary called Surface Pharmaceuticals Inc., according to an Imprimis press release.
Surface Pharmaceuticals will seek FDA approval for three drug candidates for up to five indications for ocular surface diseases, including dry eye and blepharitis, the release said.
The subsidiary will be managed and funded outside of Imprimis, and Imprimis expects Kamran Hosseini, MD, PhD, to be the CEO of Surface, once it is funded. Surface’s board will be chaired by OSN Chief Medical Editor Richard L. (Read more...)
Uncategorized